Lamivudine resistance develops in up to 80% of patients with chronic hepatitis B (CHB) after 5 years of treatment. Cross-resistance between nucleoside/nucleotide analogues limits management options in these patients. To investigate the role of pegylated interferon-α2a as rescue therapy in these patients, the efficacy and safety of pegylated interferon-α2a between treatment-naive patients and lamivudine-resistant patients with hepatitis B e antigen (HBeAg)-positive CHB were compared.
Methods
A total of 150 HBeAg-positive CHB patients were stratified according to prior treatment. Lamivudine-resistant patients (n=64) and treatment-naive patients (n=86) received pegylated interferon-α2a once-weekly for 48 weeks and were followed-up for an additional 24 weeks. Primary end points were HBeAg loss and HBV DNA <100,000 copies/ml at end of follow-up.
Results
A total of 65 (76%) treatment-naive patients and 49 (77%) lamivudine-resistant patients completed treatment and 24 weeks of follow-up. Rates of HBeAg loss were comparable at end of follow-up between treatment-naive patients and lamivudine-resistant patients (20.9% and 23.4%, respectively; P=0.8423). Similarly, rates of HBV DNA<100,000 copies/ml were comparable at end of follow-up between treatment-naive patients and lamivudine-resistant patients (20.9% and 21.9%, respectively; P=1.000). There was no statistically significant difference in alanine aminotransferase normalization rates between treatment-naive patients and lamivudine-resistant patients (36.0% and 29.7%, respectively; P=0.4848). A total of one patient in each group achieved hepatitis B surface antigen (HBsAg) loss and seroconversion. The most common adverse events were those known to occur with pegylated interferon-α2a therapy, and safety profiles were similar between both patient populations.
Conclusions
Pegylated interferon-α2a may be effective as a rescue therapy in patients with lamivudine-resistant HBeAg-positive CHB.
References
1.
LocarniniS.Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int2008; 2: 147–151.
2.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t) ide analogues. Gastroenterology2009; 137: 1593–1608.
3.
LaiC.L., DienstagJ., SchiffE.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis2003; 36: 687–696.
4.
LiawY.F., KaoJ.H., PiratvisuthT.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int2012; 6: 531–561.
5.
MarcellinP., SungJ., PiratvisuthT.Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int2010; 30: 657–668.
6.
TenneyD.J., RoseR.E., BaldickC.J.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology2009; 49: 1503–1514.
7.
TenneyD.J., PokornowskiK.A., RoseR.E.Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol2009; 50: S10.
8.
LeeY.S., SuhD.J., LimY.S.Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology2006; 43: 1385–1391.
9.
RaptiI., DimouE., MitsoulaP., HadziyannisS.J.Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology2007; 45: 307–313.
10.
YeonJ.E., YooW., HongS.P.Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut2006; 55: 1488–1495.
11.
ToyamaT., IshidaH., IshibashiH.Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B. Hepatol Res2012; 42: 1168–1174.
12.
European Association for the Study of the Liver.EASL Clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol2012; 57: 167–185.
MarcellinP., BoyerN., PiratvisuthT.Efficacy and safety of peginterferon alpha-2a (40KD) (Pegasys) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues - the PEGALAM cohort. J Hepatol2006; 44: S187.
15.
XuD.Z., XieY., WeiL.Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-positive chronic hepatitis B. J Hepatol2008; 48: S266.
16.
SunJ., HouJ.L., XieQ.Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther2011; 34: 424–431.
17.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med2005; 352: 2682–2695.
18.
LeemansW.F., FlinkH.J., JanssenH.L., NiestersH.G., SchalmS.W., de ManR.A.The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol2006; 44: 507–511.
19.
VassiliadisT., PatsiaouraK., TziomalosK.Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol2006; 12: 2417–2422.
20.
HouJ., SunJ., XieQ.Efficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil (ADV) in treating lamivudine resistant HBeAg positive CHB: an interim analysis of a prospective randomized study. Hepatology2008; 48: 745A.
21.
HongS.P., KimN.K., HwangS.G.Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol2004; 40: 837–844.
22.
MoucariR., KorevaarA., LadaO.High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol2009; 50: 1084–1092.
23.
van ZonneveldM., HonkoopP., HansenB.E.Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology2004; 39: 804–810.
24.
FattovichG., GiustinaG., Sanchez-TapiasJ.Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol1998; 93: 896–900.
25.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet2005; 365: 123–129.
26.
LiawY.F., JiaJ.D., ChanH.L.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology2011; 54: 1591–1599.
27.
ChaC.H., SohnY.H., KoS.Y., OhH.B.[Subgenotype and serotype analysis of hepatitis B virus in Korean chronic hepatitis B patients under treatment]. Korean J Lab Med2009; 29: 53–58. Korean.
28.
WaiC.T., ChuC.J., HussainM., LokA.S.HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology2002; 36: 1425–1430.
29.
FlinkH.J., van zonneveldM., HansenB.E.Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol2006; 101: 297–303.
30.
LinC.L., KaoJ.H.The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol2011; 26: 123–130.
31.
ter BorgM.J., HansenB.E., BigotG., HaagmansB.L., JanssenH.L.ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol2008; 42: 160–164.
32.
LiawY.F.On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther2009; 14: 13–22.
33.
BusterE.H., FlinkH.J., CakalogluY.Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology2008; 135: 459–467.
34.
WongV.W., WongG.L., YanK.K.Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology2010; 51: 1945–1953.
